@FierceMedDev: Syneron fattens revenue with slim-down, North American focus. More | Follow @FierceMedDev
@MarkHFierce: The latest weekly edition of FierceDiagnostics is ready for viewing. Check it out, and spread the word. Issue | Follow @MarkHFierce
@MichaelGFierce: Brain tumors succumb to drugs delivered via bone scaffold. News | Follow @MichaelGFierce
> Mindray Medical ($MR) said it has reached a settlement with Beckman Coulter ($BEC), an OEM manufacturing customer, regarding a commercial dispute. Mindray will take a $15 million charge in the 2013 fourth quarter concerning the litigation. Item
> Becton Dickinson ($BDX) said it has joined the National Patient Safety Foundation Corporate Council to promote improvements in patient safety. Item
> Second Sight Medical Products said that Popular Science magazine named its Argus II Retinal Prosthesis System as "invention of the year." Item
> Cincinnati Children's Hospital Medical Center invested $1 million in diagnostics startup Claritas Genomics in Cambridge, MA, a spinout of Boston Children's Hospital and Life Technologies ($LIFE). Story (sub. req.)
> A group of Harvard University undergraduate students designed a disposable, electronic chemotherapy patch. Story
Biotech News
@FierceBiotech: GeNO, uniQure look to leap through biotech IPO window in Q4 rush. More | Follow @FierceBiotech
@JohnCFierce: True, first wave of cancer vaccines has been a disappointment. Good reason for skepticism as well--but that's almost always the case. | Follow @JohnCFierce
@DamianFierce: Updated: Roche taps immatics in immunotherapy cancer R&D deal worth up to $1B. More | Follow @DamianFierce
@EmilyMFierce: Yale study: Left-handed people have higher rates of schizophrenia, other psychotic disorders. News | Follow @EmilyMFierce
> Troubled Transcept ditching 43% of staff with eye on getting bought. Article
> Merck KGaA adds $232M China R&D partnership to growing cancer drug collaboration. More
> Helpful regulators, blockbuster drug strategy deliver a crop of major breakthroughs. Item
Pharma News
@FiercePharma: Tuesday's top news: Breakthrough hep C meds aren't yet for sale, but critics already taking aim at prices. Story | Follow @FiercePharma
@EricPFierce: Actavis takes aim at North Carolina plant, 310 jobs, as it looks to cut costs. More | Follow @EricPFierce
@CarlyHFierce: CFR chief angles for meeting with Adcock Ingram after top investor nixes $1.3B deal. Story | Follow @CarlyHFierce
> 2013's story: Fewer drug approvals, better selling drugs. Article
> AstraZeneca wins, Merck and AbbVie lose with new statin-use guidelines. Story
> Is Endo on the verge of a Valeant-type acquisition binge? Article
> Sanofi tries label gambit to hold off Nasacort copies. More
Drug Delivery News
> MedImmune taps Unilife for wearable biologic injectable tech. Report
> DNA-delivering patch spurs bone growth. Story
> Study: Once-toxic peptide may deliver large molecules. Article
> Sustained-release glaucoma treatment nets $25M for Liquidia's Envisia. More
> Brain tumors succumb to drugs delivered via bone scaffold. Report
> Carbon nanotubes sneak drugs past gatekeeper proteins. Item
Diagnostics News
> Response Genetics sees disappointing Q3 as Dx revenue declines. Story
> VolitionRx, heartened by early data, shifts to multiple colorectal cancer Dx studies. Article
> Ex-Sequenom CEO seeks compensation in wake of scandal-related firing. More
> Oxford Immunotec's Dx milestones could supercharge IPO. Report
> Myriad gears up for melanoma test rollout. Story
> Myriad's signature BRCA test continues to generate lion's share of revenue. Item
Biomarkers News
> Study: Left-handed people have higher rates of schizophrenia, other psychotic disorders. Story
> J&J, nonprofits fund new research into links between Down syndrome, Alzheimer's. More
> Protein in damaged tissue could be biomarker for muscular dystrophy. Article
> Biomarker could predict preeclampsia in pregnant women. Report
> U.K. crew eyes biomarker as flag for atrial fibrillation complications. Story
> Researchers flag protein biomarker for aggressive oral cancer. Item
